Lead Sponsor

Hoffmann-La Roche

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•Female patients with breast cancer starting a treatment including oral and/or parenteral anti-cancer drugs (chemotherapy and/or targeted therapies, hormonotherapy)
•Inter-cycle duration between hospital visits ≥14 days (this period of time is estimated to be consistent with a need for support during the home setting period)
•Patients shall be prescribed loperamide or any other anti-diarrheic treatment in case of diarrhea and prescription for any medication indicated in case of nausea/vomiting
•Able to speak and read French and to use a smartphone embedding ZEMY, in the investigator's judgment
•Able to comply with the study protocol, in the investigator's judgment
•Patient affiliated to the national social security or beneficiary to such insurance.

•Pregnant
•Already enrolled in a clinical study involving experimental medication or eHealth device
•Concomitant malignancy
•ECOG score \>2
•Treated with single hormonotherapy, single surgery or single radiotherapy, immunotherapy.
•Patient whose mental state renders her unable to understand the nature, purposes, and consequences of the study
•Patient not trained to the use of ZEMY
•Patient not trained to take her blood pressure measurement
•Patient deprived of her liberty by judicial or administrative order.

Related studies

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

NCT06347068 · Breast Cancer, Relapse, and more

NCT07655934 · Breast Cancer

NCT06400563 · Breast Cancer

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment